Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility | 470 | Business Wire | Subscription of €2.6 million, representing 100% of the initial amount Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring Bpifrance now... ► Artikel lesen | |
02.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 143 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
30.06. | Advicenne Confirms the Upcoming Filing for Registration of ADV7103 in the USA and is Securing Its Financing Through Loan Restructuring and the Launch of a Rights Issue. | 274 | Business Wire | Submission of the US marketing authorization application for ADV7103 planned in Q4 2025, following positive feedback from the FDA on the additional data submitted. Repayment of tranches... ► Artikel lesen | |
29.04. | ADVICENNE: Advicenne met à disposition son Document d'Enregistrement Universel 2024 | 2 | Euronext | ||
29.04. | Advicenne 2024 Universal Registration Document Made Available | 229 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
27.03. | Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States | 451 | Business Wire | Total product sales of Advicenne up 9.4% to €4.9m
Operating cash consumption below €1M by 2025 and significant improvement in cash flow
Cash position of €3.2 million on December... ► Artikel lesen | |
29.01. | Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria | 411 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
ADVICENNE Aktie jetzt für 0€ handeln | |||||
23.01. | Advicenne Announces 2024 Gross Sales1 | 409 | Business Wire | 2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024... ► Artikel lesen | |
19.12.24 | Advicenne Finalizes Agreement with Primex Pharmaceuticals AG | 465 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
28.11.24 | Advicenne Announces its 2025 Financial Calendar | 168 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
01.10.24 | Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103 | 426 | Business Wire | FDA agrees to submission of a marketing authorization application for ADV7103 in dRTA without further clinical studies. The positive orphan drug designation decision for ADV7103 in cystinuria... ► Artikel lesen | |
18.09.24 | Advicenne Reports Its First Half Financial Results as of June 30, 2024, and Updates on Its Activities | 448 | Business Wire | Sibnayal® gross sales up 28% to €1.25 million including royalties paid by commercial partners (16% excluding royalties) Continued progress towards current operating breakeven Cash... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 20,895 | +0,63 % | Bristol Myers Squibb, Pfizer Announce Direct-to-patient Option For Eliquis | NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) and Pfizer (PFE) Thursday announced a direct-to-patient option for purchasing their blood thinner medicine, Eliquis through the partnership's... ► Artikel lesen | |
ABBVIE | 158,80 | +0,38 % | Dividendenbekanntmachungen (15.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,59 USD 0,5058 EUR ABBVIE INC US00287Y1091 1,64 USD 1,4059 EUR ARCOSA INC US0396531008 0,05... ► Artikel lesen | |
HAEMATO | 10,500 | -0,94 % | M1 Kliniken: Verkauf von HAEMATO PHARM im Fokus | Die M1 Kliniken AG steht vor dem möglichen Verkauf eines Teils der Konzern-Aktivitäten: Die zur Gruppe gehörende HAEMATO AG prüft derzeit ein verbindliches Angebot für den Verkauf ihrer Tochtergesellschaft... ► Artikel lesen | |
HALEON | 4,074 | -0,17 % | FTSE 100 Index shares forecast: Lloyds, Vodafone, BP, Haleon | ||
ACHIEVE LIFE SCIENCES | 2,240 | -1,75 % | Achieve Life Sciences: Trading-Chance bei Anti-Raucher-Aktie | SD-Leser kennen die Aktie von Achieve Life Sciences von früheren Höhenflügen noch gut. Immer wieder konnten wir uns gezielt Trading-Dynamiken zunutze machen und teils dreistellige Gewinne einfahren.... ► Artikel lesen | |
LIGAND PHARMACEUTICALS | 119,00 | -1,65 % | LGND AI: $9 Million Secured For Improving Earth Data | ||
ROYALTY PHARMA | 30,220 | +0,30 % | Royalty Pharma announces $0.22 per share dividend for Q3 2025 | ||
EISAI | 22,220 | -3,81 % | Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab | TOKYO, July 16, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the drug discovery research for Lecanemab (product name: "LEQEMBI"), a humanized... ► Artikel lesen | |
DR REDDYS | 12,300 | 0,00 % | Dr Reddy's Lab receives EIR from USFDA for Middleburgh API facility | ||
TG THERAPEUTICS | 32,180 | +0,55 % | TG Therapeutics, Inc.: TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance | First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to... ► Artikel lesen | |
VERONA PHARMA PLC ADR | 89,60 | -0,22 % | Verona Pharma stock reaches all-time high at 105.0 USD | ||
BETTERLIFE PHARMA | 0,051 | 0,00 % | Betterlife Pharma Inc (2): Betterlife Pharma extends 2.95 million warrants | ||
ENTOURAGE HEALTH | 0,001 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.04.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 08.04.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.04.2025ISIN NameCA2938611001 ENTOURAGE... ► Artikel lesen | |
KYOWA KIRIN | 14,100 | -2,76 % | Dividendenbekanntmachungen (27.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGC INC JP3112000009 105 JPY 0,6216 EUR ALERUS FINANCIAL CORPORATION US01446U1034 0,21 USD 0,1795 EUR ALICO INC US0162301040 0... ► Artikel lesen | |
IGC PHARMA | 0,310 | -1,27 % | IGC Pharma, Inc.: IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards | POTOMAC, MD / ACCESS Newswire / July 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scientist... ► Artikel lesen |